持续性C反应蛋白升高与中轴型脊柱关节炎内皮功能障碍关系的分子机制研究
245例中轴型脊柱关节炎患者中,40%存在持续性CRP升高,其代谢合并症、动脉粥样硬化斑块患病率更高且微血管内皮功能更差。蛋白组学发现IL-6、CDCP-1与内皮功能障碍相关,PON-3是唯一下调蛋白并在体外恢复内皮功能。抗TNF-α治疗改善代谢和炎症指标并调节上述蛋白水平。
要点
- 40%中轴型脊柱关节炎患者存在持续性CRP升高,与代谢合并症增多、动脉粥样硬化斑块患病率升高及微血管内皮功能更差相关。
- 蛋白组学识别10种差异蛋白,IL-6和CDCP-1与内皮功能障碍、更高颈动脉内膜中层厚度及代谢紊乱相关,PON-3为唯一下调蛋白并在体外恢复内皮功能。
- 抗TNF-α治疗降低炎症标志物、补体成分和致动脉粥样硬化指数,升高高密度脂蛋白、载脂蛋白A和PON-3水平,降低IL-6和CDCP-1水平。
核心结论
- 中轴型脊柱关节炎中持续性CRP升高与心血管风险增加、内皮功能障碍和动脉粥样硬化密切相关。
- IL-6、CDCP-1和PON-3是连接炎症与心血管风险的关键介质。
- 抗TNF-α治疗改善代谢和炎症特征并调节IL-6、CDCP-1和PON-3水平,支持其在管理中轴型脊柱关节炎心血管风险中的作用。
研究设计与样本
- 纳入245例中轴型脊柱关节炎患者,测量颈动脉内膜中层厚度和微血管内皮功能(缺血后反应性充血)。
- 根据过去5年回顾性CRP测量结果,以超过50%的读数升高定义为持续性高CRP。
- 采用邻近延伸分析检测184种炎症和心血管疾病相关蛋白的血清水平,并在人脐静脉内皮细胞中进行体外研究。
主要发现
- 40%的中轴型脊柱关节炎患者存在持续性CRP升高,与间歇性CRP升高者相比代谢合并症增加、动脉粥样硬化斑块患病率更高且微血管内皮功能更差。
- 蛋白组学分析识别10种改变蛋白,IL-6和CDCP-1与内皮功能障碍、更高颈动脉内膜中层厚度及代谢紊乱相关。
- PON-3是唯一下调蛋白,具有抗炎、抗氧化和抗动脉粥样硬化特性,在体外恢复内皮功能。
- CDCP-1与动脉粥样硬化斑块相关,并在体外促进内皮黏附、氧化应激和炎症。
- 抗TNF-α治疗降低炎症标志物、补体成分和致动脉粥样硬化指数,升高高密度脂蛋白、载脂蛋白A和PON-3水平,降低IL-6和CDCP-1水平。
临床怎么用
- 原文结论指出抗TNF-α治疗改善代谢和炎症特征并调节IL-6、CDCP-1和PON-3水平,支持其在管理中轴型脊柱关节炎心血管风险中的作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the impact of sustained C reactive protein (CRP) elevation on cardiovascular (CV) risk factors, particularly endothelial dysfunction and atherosclerosis, in axial spondyloarthritis (axSpA) patients and to explore the underlying molecular mechanisms. METHODS: 245 axSpA patients were enrolled. Carotid intima-media thickness (CIMT) and microvascular endothelial function (post-ischaemic reactive hyperaemia) were measured. Retrospective CRP measurements from the past 5 years classified patients as having sustained high CRP if >50% of readings were elevated. Serum levels of 184 inflammation and CV disease-related proteins were analysed using a proximity extension assay, and in vitro studies were conducted in human umbilical vein endothelial cells. RESULTS: 40% of axSpA patients had sustained CRP elevation, showing increased metabolic comorbidities, higher prevalence of atherosclerotic plaques and worse microvascular endothelial function compared with those with intermittent CRP elevations. Proteomic analysis identified 10 altered proteins, with interleukin 6 (IL-6) and CUB domain-containing protein 1 (CDCP-1) linked to endothelial dysfunction, higher CIMT and metabolic disturbances. Paraoxonase 3 (PON-3), the only downregulated protein, showed anti-inflammatory, antioxidant and antiatherogenic properties, restoring endothelial function in vitro. CDCP-1 was associated with atherosclerotic plaques and promoted endothelial adhesion, oxidative stress and inflammation in vitro. Anti-TNF-α therapy reduced inflammatory markers, complement components and the atherogenic index, while increasing high density lipoprotein, apolipoprotein A and PON-3 levels and decreasing IL-6 and CDCP-1 levels. CONCLUSIONS: Sustained CRP elevation in axSpA is strongly linked to increased CV risk, endothelial dysfunction and atherosclerosis. IL-6, CDCP-1 and PON-3 emerge as key mediators connecting inflammation to CV risk. Anti-tumour necrosis factor-α therapy improved the metabolic and inflammatory profile and modulated IL-6, CDCP-1 and PON-3 levels, supporting its role in managing CV risks in axSpA.
引用
- Cuesta-López L, Arias-de la Rosa I, Martín-Salazar JE, et al. Molecular insights into the relationship between sustained CRP elevation and endothelial dysfunction in axial spondyloarthritis. RMD Open. 2025. PMID: 40617584. doi:10.1136/rmdopen-2025-005746
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。